NASDAQ:PBLA Panbela Therapeutics (PBLA) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free PBLA Stock Alerts $0.38 -0.03 (-7.29%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$0.38▼$0.4850-Day Range$0.41▼$1.2752-Week Range$0.35▼$300.00Volume61,762 shsAverage Volume65,646 shsMarket Capitalization$1.33 millionP/E RatioN/ADividend YieldN/APrice Target$500.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Panbela Therapeutics alerts: Email Address Panbela Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside131,030.3% Upside$500.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($3.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.66 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPanbela Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePanbela Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PBLA. Previous Next 0.0 Dividend Strength Dividend YieldPanbela Therapeutics does not currently pay a dividend.Dividend GrowthPanbela Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBLA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Panbela Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for PBLA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Panbela Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Panbela Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 4.37% of the stock of Panbela Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Panbela Therapeutics are expected to grow in the coming year, from ($5.25) to ($3.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Panbela Therapeutics Stock (NASDAQ:PBLA)Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Read More PBLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBLA Stock News HeadlinesMay 1, 2024 | globenewswire.comPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024April 30, 2024 | globenewswire.comAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekMay 3, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.April 26, 2024 | americanbankingnews.comPanbela Therapeutics (NASDAQ:PBLA) Trading 7.3% Higher April 22, 2024 | globenewswire.comPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025April 18, 2024 | marketwatch.comPanbela Applies to List on CBOEApril 18, 2024 | globenewswire.comPanbela Announces Poster Presentation at American Association for Cancer Research:April 17, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB MarketMay 3, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.April 16, 2024 | finance.yahoo.comPanbela Announces Transfer to OTCQB MarketMarch 28, 2024 | benzinga.comRecap: Panbela Therapeutics Q4 EarningsMarch 28, 2024 | seekingalpha.comPanbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsMarch 26, 2024 | globenewswire.comPanbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsMarch 26, 2024 | benzinga.comEarnings Preview: Panbela TherapeuticsMarch 22, 2024 | seekingalpha.comPBLA Panbela Therapeutics, Inc.March 12, 2024 | globenewswire.comPanbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024February 23, 2024 | msn.comTop 4 Health Care Stocks That Are Preparing To Pump This MonthFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)February 15, 2024 | finance.yahoo.comPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsFebruary 15, 2024 | globenewswire.comPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsFebruary 1, 2024 | finance.yahoo.comPanbela Announces Closing of Approximately $9.0 Million Public OfferingJanuary 31, 2024 | investing.comPanbela Therapeutics Inc (PBLA)January 30, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)January 30, 2024 | benzinga.comWhat's Going On With Panbela Therapeutics Stock Today?January 30, 2024 | finance.yahoo.comAcceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)See More Headlines Receive PBLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/02/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PBLA CUSIPN/A CIK1029125 Webwww.panbela.com Phone(952) 479-1196FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$500.00 High Stock Price Target$500.00 Low Stock Price Target$500.00 Potential Upside/Downside+131,030.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($669.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70,194.55% Return on Assets-172.92% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.37) per share Price / Book-0.02Miscellaneous Outstanding Shares3,480,000Free Float3,481,000Market Cap$1.33 million OptionableNot Optionable Beta1.55 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Jennifer K. Simpson CRNP (Age 56)M.S.N., Ph.D., CEO, President & Director Comp: $527kMs. Susan Horvath (Age 65)VP of Finance, CFO, Secretary & Treasurer Comp: $452.39kMs. Tammy GroeneVice President of OperationsDr. Elizabeth Bruckheimer Ph.D.VP & Chief Scientific OfficerKey CompetitorsHistogenNASDAQ:HSTOLucy Scientific DiscoveryNASDAQ:LSDINeuBase TherapeuticsNASDAQ:NBSEGRI BioNASDAQ:GRIInMed PharmaceuticalsNASDAQ:INMView All CompetitorsInsidersGoldman Sachs Group IncSold 3,643 sharesTotal: $51,730.60 ($14.20/share)View All Insider Transactions PBLA Stock Analysis - Frequently Asked Questions Should I buy or sell Panbela Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBLA shares. View PBLA analyst ratings or view top-rated stocks. What is Panbela Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 12-month price objectives for Panbela Therapeutics' shares. Their PBLA share price targets range from $500.00 to $500.00. On average, they anticipate the company's stock price to reach $500.00 in the next year. This suggests a possible upside of 131,030.3% from the stock's current price. View analysts price targets for PBLA or view top-rated stocks among Wall Street analysts. How have PBLA shares performed in 2024? Panbela Therapeutics' stock was trading at $18.30 at the beginning of 2024. Since then, PBLA shares have decreased by 97.9% and is now trading at $0.3813. View the best growth stocks for 2024 here. How were Panbela Therapeutics' earnings last quarter? Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings results on Tuesday, March, 26th. The company reported ($65.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($24.34) by $41.56. When did Panbela Therapeutics' stock split? Panbela Therapeutics shares reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Panbela Therapeutics? Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PBLA) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
